Myotonic dystrophy type 1 (DM1) is a complex multisystemic disorder caused by an expansion of a CTG repeat located at the 3′ untranslated region (UTR) of DMPK on chromosome 19q13.3. Aberrant messenger RNA (mRNA) splicing of several genes has been reported to explain some of the symptoms of DM1 including insulin resistance, muscle wasting and myotonia. In this paper we analyzed the expression of the MYH14 mRNA and protein in the muscle of DM1 patients (n = 12) with different expansion lengths and normal subjects (n = 7). The MYH14 gene is located on chromosome 19q13.3 and encodes for one of the heavy chains of the so called class II "nonmuscle" myosins (NMHCII). MYH14 has two alternative spliced isoforms: the inserted isoform (NMHCII-C1) which includes 8 amino acids located in the globular head of the protein, not encoded by the non inserted isoform (NMHCII-C0). Results showed a splicing unbalance of the MYH14 gene in DM1 muscle, with a prevalent expression of the NMHCII-C0 isoform more marked in DM1 patients harboring large CTG expansions. Minigene assay indicated that levels of the MBNL1 protein positively regulates the inclusion of the MYH14 exon 6. Quantitative analysis of the MYH14 expression revealed a significant reduction in the DM1 muscle samples, both at mRNA and protein level. No differences were found between DM1 and controls in the skeletal muscle localization of MYH14, obtained through immunofluorescence analysis. In line with the thesis of an "RNA gain of function" hypothesis described for the CTG mutation, we conclude that the alterations of the MYH14 gene may contribute to the DM1 molecular pathogenesis.
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1. Introduction
The myotonic dystrophy type 1 spliceopathy
Myotonic dystrophy type 1 (DM1; OMIM 160900) is the most prevalent form of muscular dystrophy in adults (Harper et al., 2001 ). This disorder is caused by the expansion of a CTG repeat in the 3′ untranslated region (UTR) of DMPK (DMPK; OMIM 605377), a gene encoding a protein kinase localized on chromosome 19q13.3 (Brook et al., 1992) . The CTG repeats are polymorphic, healthy individuals that have 5-38 CTG repeats whereas individuals with DM1 have repeats in the hundreds to thousands (Zerylnick et al., 1995) . The clinical aspects of the disease include myotonia, progressive muscle weakness, cataracts, insulin resistance and cardiac conduction defects (Harper et al., 2001) . Three forms of DM1 are usually recognized: congenital DM1 (CDM), which is associated with generalized muscular hypotonia, talipes, and mental retardation; juvenile/adult DM1, phenotypically variable, with myotonia, muscle weakness, cardiac arrhythmias, male balding, hypogonadism, psychocognitive dysfunction, and glucose intolerance; and late adult/senile DM1, seen in middle-to-old-age and characterized by cataracts, baldness, and minimal or absent muscle involvement (Machuca-Tzili et al., 2005) . The main pathogenic process at the basis of DM1 is a toxic RNA-gain of function effect of mutant DMPK transcripts which are retained in distinct ribonuclear foci within cells (Davis et al., 1997) . A current model of the disease mechanism hypothesizes that CUG expanded tracts alter the function of at least two RNA-binding proteins involved in the alternative splicing process: the muscleblind-like 1 protein (MBNL1) and the CUG-binding protein 1 (CUGBP1) (Dansithong et al., 2005; Kuyumcu-Martinez et al., 2007; Miller et al., 2000) . It has been proposed that the MBNL1 loss of function, through a physical interaction with the CUG-repeats, and the CUGBP1 protein increased steady state level, due to a PKC mediated nuclear hyperphosphorylation, act synergistically in the splicing misregulation of a wide group of developmentally regulated genes (Kuyumcu-Martinez et al., 2007; Ranum, 2006) . These include cardiac troponin T (c-TNT), insulin receptor (IR), muscle specific chloride channel (CLCN-1) and the dystrophin gene in skeletal muscle, the microtubule-associated tau, NMDA receptor 1 and amyloid precursor protein in the brain (Sergeant et al., 2001; Kalsotra et al., 2008; Osborne et al., 2009) . In all cases the splicing regulation is disrupted, resulting in preferential expression of aberrant spliced isoforms not appropriate for a particular tissue or developmental stage. Among the symptoms of DM1, myotonia and insulin resistance are attributed to the disruption of the CLCN-1 and IR alternative splicing, respectively (Charlet et al., 2002; Savkur et al., 2001 ). Moderate to severe hearing loss, usually sensorineural, has also been reported in DM1 patients (Wright et al., 1988) and the risk of developing serious hearing impairment is much greater for adult patients in all age brackets when compared to the general population (Wright et al., 1988) . However, the cause of hearing problems in DM1 patients is not well defined.
Hearing loss and mammalian non muscle myosin heavy-chain gene MYH14
Hereditary hearing loss is caused, in 50% of cases, by single gene mutations, including myosins, connexins, transcription factors, potassium channels or other cellular components that play an important role in ear cells (Hilgert et al., 2009; Van Laer et al., 2003) . Different members of the myosin superfamily are responsible for syndromic and non-syndromic hearing impairment transmitted as an autosomal dominant or recessive trait (Friedman et al., 1999) . Mammalian non muscle myosin IIs (NM-IIs) are exameric proteins composed of two heavy chains and two pairs of light chains that self associate to form bipolar filaments that pull on actin filaments to produce the force that drives important cellular functions, such as cytokinesis, cell polarity and cell migration (Sellers, 2000) . The term "nonmuscle myosin" was generally used to distinguish between the ubiquitous forms of myosin II and the muscle-specific isoforms. However, this term is misleading because these myosins are not only expressed in all types of nonmuscle tissue but also have a significant role in the development and function of smooth and skeletal muscles (Morano et al., 2000; Takeda et al., 2000; Tullio et al., 1997) . Three isoforms of the non-muscle myosin heavy chain (NMHC), II-A, II-B, II-C have been identified in vertebrates (Golomb et al., 2004; Katsuragawa et al., 1989) , and are the product of three different genes: MYH9, MYH10 and MYH14, respectively in humans (Leal et al., 2003; Simons et al., 1991) . These myosins have a very high sequence homology both inter and intra species (Golomb et al., 2004 ) and although MYH14 is still called "nonmuscle myosin" it is highly expressed in skeletal muscle like the other two nonmuscle myosins (Leal et al., 2003) . The MYH14 gene is located on chromosome 19q13.3, inside the DFN4A region associated with a non-syndromic autosomal dominant deafness (Donaudy et al., 2004; Pusch et al., 2004) . The gene is composed of 41 exons and is transcribed as a main 7 kb mRNA which encodes for a potential polypeptide of 1995 aa and a calculated 228 kDa molecular weight (Leal et al., 2003) . The identification of point mutations in large pedigrees linked to DFN4A clearly demonstrates the role of MYH14 in causing autosomal dominant hearing loss and further confirms the crucial role of the myosin superfamily in auditive functions (Yang et al., 2005) . Previous studies about this gene have identified at least two alternatively spliced isoforms across exon 6 which encode for the NMHC II-C0 and NMHC II-C1 isoforms differing by 8 aminoacids inserted into loop 1 in the globular head of the protein (Golomb et al., 2004) . Interestingly, this insertion is near the ATP-binding region of NMHC II-C and increases both actin-activated MgATPase enzymatic activity and in vitro motility in translocating actin filaments of the inserted isoform (Kim et al., 2005) . The purpose of the present study was to determine the expression profile of the MYH14 gene at the mRNA and protein level in DM1 muscle tissues. To accomplish this, we analyzed 12 skeletal muscle biopsies from DM1 patients harboring different CTG expansions and 7 muscle biopsies from healthy controls. We found a splicing unbalance of the MYH14 gene in DM1 muscle, with a prevalent expression of the MYH14 Δ6 , not inserted isoform, mainly in patients with large DM1 mutations. An aberrant splicing regulation of the Myh14 transcript has also been observed in the muscular tissue of the DMSXL mice models of DM1 with changes opposite to those in the muscle samples from patients. Quantitative analysis of the MYH14 expression revealed a significant reduction in the DM1 muscle samples at both mRNA and protein levels, whereas no differences have been found in the skeletal muscle localization of the MYH14 protein between DM and control tissues. In vitro minigene assays demonstrated that MBNL1 directly regulates the splicing of MYH14 pre-mRNA inducing the inclusion of exon 6. These findings indicate that the sequestration of MBNL1 in the CUG repeat expansion could lead to the expression of a MYH14 shorter isoform which could play a role in the muscular and hearing impairment typical of DM1 patients.
Methods

Skeletal muscle biopsies and patients' clinical data
DM1 muscle samples (n= 12) and controls samples (n = 7) were diagnostic open biopsies from vastus lateralis provided by Telethon Biobank No. GTB07001. All muscle biopsies were frozen in melting isopentan immediately after surgery, and stored at −80°C until used. Histological analysis of DM1 biopsies showed the typical pathology of the disease, including increased fiber size variation, atrophic fibers, pyknotic nuclear clamps, and marked prevalence of centrally located nuclei. DM1 patients were diagnosed at the Department of Neurology, University of Padua, Padua, Italy. The diagnosis of DM1 was based on clinical, electromyographic (high frequency repetitive discharges), ophthalmologic and cardiac investigations. In our cohort of patients, the degree of muscle impairment was assessed by using the Muscular Impairment Rating Scale (MIRS) (Mathieu et al., 2001) . In addition to the MIRS we also assessed cognitive impairment, cataract, cardiac involvement, endocrine dysfunctions and motor impairment (Table 1) . 
Molecular analysis
Genomic DNA was extracted from skeletal muscle using a saltingout procedure (Miller et al., 1988) . (CTG) repeat expansion sizes were determined by a combination of long-PCR and Southern blot analysis (Botta et al., 2006) . Expanded fragments were sized by measuring the bands of major intensity which presumably corresponds to the more representative alleles. DM1 mutation in our muscle samples ranged from 150 up to 2000 (CTG)s (Tab.1).
QRT-PCR and splicing analysis
Total RNA was extracted from frozen muscle biopsies using TRI reagent (Molecular Research Center, Inc.). Three micrograms of total RNA was reverse transcribed according to the cDNA protocol of the High Capacity cDNA Archive kit (Applied Biosystem, Foster City, CA). The expression level of the MYH14 gene was measured by Real-Time quantitative PCR (QRT-PCR) using the Hs00226855_m1 Assay-ondemand TM gene expression product, labeled with FAM-dye. The relative MYH14 gene expression level in each cDNA sample has been obtained by a multiplex QRT-PCR reaction using a human β2-microglobulin (β2M) specific probe labeled with VIC™ MGB dye as internal control gene (TaqMan assay # Hu β2M 4326319 E). Each PCR reaction was performed in triplicate using the TaqMan™ gene expression Master Mix and the ABI PRISM 7000 Sequence Detection System (Applied Biosystem, Foster City, CA). A comparative threshold cycle (Ct) was used to determine gene expression. For each sample, MYH14 Ct value was normalized with the internal control gene using the formula ΔCt = Ct MYH14 − Ct β2M . The distribution of ΔCt between DM1 samples and controls has been analyzed using a t-Student statistical analysis. The RT-PCR splicing assay to study the two alternative MYH14 isoforms was performed according to a reported protocol using primers across the exon 6 gene region (Jana et al., 2006) . Total PCR products, obtained within the linear range of amplification, were electrophoresed on 3% agarose gel. The MYH14-ex6 /MYH14 Δ6 isoform ratio has been quantified by a QRT-PCR assay specific for the two different MYH14 gene isoforms using the β2M transcript as internal control. Primers and probes across exon 6 and exons 5-7 have been designed on demand by Applied Biosystem on the basis of the MYH14 gene transcript sequence (GenBank Accession number #NM_001077186.1). The MYH14 isoform not including exon 6 has been detected with the following set of primers and probe: primer F 5′-TCTCCAAAGGGCAGGAAGGA-3′, probe 5′-CTCACCGGGGACACCC-3′ FAM labeled, primer R 5′-ATGGGGTTGGCCTGAAGCA-3′. The MYH14 ex6 isoform have been measured with primer F 5′-TCTCCAAAGGGCAG-GAAGGA-3′, probe 5′-CCGTCAGCACCGTGTCT-3′ FAM labeled and primer R 5′-CCGCTCCAGCTCACCATA3′.
Construction of plasmids for MYH14 minigene assay
To construct the mini-gene that includes MYH14 exons 5-7 (pcMYH2.5) the human genomic sequence of MYH14 (RefSeqGene NG_011645.1) containing 32 bp of intron 4, exon 5-intron 5-exon 6-intron 6-exon 7 and of 90 bp of intron 7, was generated by PCR using the following primer sets: forward (MYHint4F 5′-AACCCCTTTGCTTCCCTT-3′) and reverse (MYHint7R 5′-ATCCACGTGTCTTTCCCCCT-3′). The approximately 2.5 kb PCR product was obtained and digested with BamHI and NotI, then subcloned in the pCR2.1 vector (Invitrogen Corp, Carlsbad, CA) and inserted into the pcDNA3.1(+) mammalian expression vector (Invitrogen Corp, Carlsbad, CA) digested with BamH1 and NotI enzymes. Standard recombinant DNA techniques were used to construct an expression plasmid for the MBNL1 isoforms 41 protein in the pEF1/-Myc-HisA vector (Invitrogen Corp, Carlsbad, CA) (pEF1MBNL1 41 ). All of the constructs were sequenced before use in the experiments. In vitro splicing constructs of human MYH14 mini-genes (4.0 μg) were transfected into rabdomiosarcoma cells using LipofectAMINE2000 reagent (Invitrogen Corp, Carlsbad, CA) according to the manufacturer's protocol. Transfected cells were lysed in TRI reagent (Molecular Research Center, Inc.) 48 h after the addition of plasmids and the total cellular RNA was purified. First strand cDNA was synthesized in a 20-μl reaction volume using the High Capacity cDNA Archive kit protocol (Applied Biosystem, Foster City, CA). PCR amplification analysis of the plasmid-derived cDNAs was performed using the primer set and the MYHint4F and pcDNA3.1/BGH reverse priming site. The reaction products were resolved by 2.5 agarose gel electrophoresis and quantitative analysis of the amplified products was carried out using a fluorimager 595 (Amersham Biosciences, Buckinghamshire, UK). The ratio of exon 6 inclusion was quantified and expressed as percentages of inclusion relative to the total intensities. Data are shown as the mean+SD of three independent experiments.
Transgenic mice
The transgenic mice used in this study carry 45 kb of human genomic DNA cloned from a DM1 patient as described by GomesPereira et al. (2007) . Animals were bred onto a mixed background (C57BL6/129/OLA/FVB). Transgenic status and CTG molecular sizing was assayed by Tail PCR using reported protocols (Seznec et al., 2000) . Total RNA has been extracted from proximal (vastus lateralis-VL) and distal (gastrocnemius-GM) skeletal muscles, brain and heart of two mice homozygous for hDMPK alleles (700/1230) at 6 months of age and two age-matched non-transgenic littermates. The ratio of the inserted and non inserted Myh14 transcripts has been determined by RT-PCR according (Golomb et al., 2004) . All experiments were performed in accordance with the Directive 2010/63/EU.
Western blotting
Ten micrometer muscle sections were collected from frozen biopsy specimens and lysed in a buffer containing 50 mM Tris pH 7.5, 150 mM NaCl, 10 mM MgCl 2 , 0.5 mM DTT, 1 mM EDTA, 10% glycerol, 2% SDS, 1% Triton X-100, Protease Inhibitor Cocktail (Sigma Aldrich) and Phosphatase Inhibitor Cocktail 1 and 2 (Sigma Aldrich). Protein amount was measured by the BCA method (Pierce) and 30 μg of each extract was run in a 4-12% T30C4 SDS-PAGE. Proteins were then blotted into a nitrocellulose membrane, probed with specific NMHCII-C 1:600 (Golomb et al., 2004) and actin 1:5000 (Santa Cruz BT) antibodies. After incubation with secondary HRP-conjugated antibodies, recognized bands were visualized by chemiluminescence (GE HealthCare). Integrated optical density of each band was calculated with commercial software and normalized compared to the actin levels.
Immunofluorescence analysis
Longitudinal and transverse muscle cryostat sections (8 μm) of normal subjects and DM1 patients were thaw-mounted on to glass slides pretreated with 3% EDTA to prevent contracture artifacts, and processed for indirect immunofluorescence (IF). After fixation in acetone for 10 min at 4°C, sections were incubated for 60 min with the anti-NMHCIIc Ab, diluted 1:100 (kindly provided by Prof. R. Adelstein), rinsed in PBS and incubated for 1 h with a TRITCconjugated goat anti-rabbit Ab (Sigma, 1:100). Negative control sections were incubated with non-immune serum instead of primary Ab. In order to evaluate localization of NMHC II-C in relation to sarcomeric components, double-labeling experiments were conducted combining the anti-NMHC II-C with an anti-slow Myosin Heavy Chain (sMHC) monoclonal Ab (Novocastra, Newcastle upon Tyne, UK, 1:10).
Results
Aberrant splicing of the MYH14 transcript in muscle tissue from DM1 patients and DMSXL transgenic mice
The gene encoding NMHC II-C undergoes alternative splicing to generate several isoforms. One of these isoforms, named NMHC II-C1, contains the alternatively spliced exon 6 that encodes for 8 amino acids close to the ATP binding region in loop 1 of the protein (Golomb et al., 2004) . The NMHC II-C1 protein is expressed in a variety of tissues and shows an increased actin-activated MgATPase activity and in vitro motility compared with the non inserted isoform (NMHC II-C0). To test whether the MYH14 gene expression is altered in DM1 patients, we investigated the expression and the splicing pattern of this gene in human skeletal muscle biopsies of 12 DM1 patients and 7 control subjects.
Total amount of MYH14 transcript was determined in DM1 muscles and in controls using a QRT-PCR approach with a MYH14-specific TaqMan assay. For each sample, MYH14 expression was normalized with the gene B2-microglobulin (B2-M) as an endogenous control. Results shown in Fig. 1 indicate the down regulation of the MYH14 transcript in the DM1 skeletal muscle compared to normal samples. In DM1 patients, the reduction of the MYH14 mRNA ranged from 19% to 88%, with no correlation with the CTG expansion grade (median control values has been set as 100%).
We also investigated the expression of the alternative spliced isoforms encoding for the NMHC II-C0 and NMHC II-C1 proteins in muscle biopsies using conventional RT-PCR with primers flanking MYH14 exon 6. Fig. 2A shows the distribution of the MYH14 ex6 (NMHCII-C1) and MYH14 Δ6 (NMHCII-C0) isoforms in our set of muscle biopsies. The figure shows that, although the inserted mRNA is predominant in control samples, DM1 muscles express an increasing amount of the non inserted isoforms proportionate to the CTG expansion grade. Quantification of the two MYH14 transcripts was calculated by QRT-PCR analysis using two different TaqMan probes specific for the MYH14 ex6 and MYH14 Δ6 isoforms respectively and the B2-M transcript as a control for the normalization of samples. The diagram in Fig. 2B indicates that the median value of the MYH14 Δ6 /MYH14 ex6 isoform ratio is 0.24 for the controls and 0.72 for the DM1 patients, with higher levels in DM1 patients harboring more than 1000 CTG repetitions. Statistical analysis of these values indicates that the difference between DM1 and controls is significant with a P valueb 0.03.
Transgenic mice offer an important model of what occurs in human patients and are powerful tools with which we can understand the pathogenesis of DM1. To further confirm the aberrant splicing of the MYH14 gene in DM1 we studied the expression of the mouse Myh14 orthologue gene (GenBank accession number #BAB26815) in the wellcharacterized DMSXL mouse model (Gomes-Pereira et al., 2007) . These mice are homozygous for the human DM1 mutation, carrying 700 CTG on one allele and more than 1000 on the other. They displayed a severe disease phenotype with very high mortality, growth retardation from birth and marked splicing abnormalities in the central nervous system and muscle (Gomes-Pereira et al., 2007) . The mouse Myh14 shows 90% identity with the human homologue gene and maintains the two alternatively spliced isoforms expressed in humans (GenBank accession numbers #AY205605 and #AY363100) encoding for proteins which contain the characteristic domains of a myosin II heavy chain. The corresponding cDNAs encode a gene product of 2000 aa for the inserted isoforms and 1992 aa for the non inserted one.
We used RT-PCR analysis to determine the ratio of the inserted and non inserted Myh14 transcripts in proximal (vastus lateralis-VL) and distal (gastrocnemius-GM) skeletal muscle, brain and heart tissues from two mice homozygous for hDMPK locus (700/1230) at 6 months of age and from two age-matched non-transgenic littermates. As reported in literature (Golomb et al., 2004) , adult mouse skeletal muscle and heart express very low amounts of the Myh14 inserted message in contrast to what is observed in the human tissues. In brain tissue there is approximately equal amounts of both mRNAs. In DMSXL mice we observed an aberrant splicing of the Myh14 gene in both VL and GM muscles with an increased expression of the inserted message (more marked in the distal muscle) compared to the wild type tissues. However, the splicing alterations found in DMSXL mice and DM1 patients are opposite, which could be explained by the different MYH14 isoform expression in the wild type tissues of mice and humans. No significant differences of the Myh14 expression profile have been found in the heart and brain between DMSXL and control mice (Fig. 3) .
To determine the cis-acting elements responsible for the aberrant splicing of the MYH14 gene, we searched the binding sequences for the MBNL1 and CUGBP1 splicing factors in MYH14 exon 6 and its 180 bp flanking intron sequences. We found 3 repeats of the specific sequence for MBNL1-binding, YGCU(U/G)Y: one located 38 nt upstream and the other two at 28 and 151 nt downstream of the exonic region. Moreover, 6 YCGY repeats (two located in intron 5 and 4 in intron 6 respectively) and several YCG or CGY motifs have been detected. Cis-elements responsible for the CUGBP1 binding (TGTTTGTTTGT or TGTGTGTGTGT) were not observed in MYH14 exon 6 and in its flanking intronic sequences. MBNL1 could therefore regulate the alternative splicing of the MYH14 gene by binding specific motifs in the intronic region flanking exon 6 leading to the missplicing observed in DM1 muscle.
To verify this hypothesis, we constructed a minigene including the human sequence of MYH14 containing 32 bp of intron 4, exon 5-intron 5-exon 6-intron 6-exon 7 and 90 bp of intron 7 cloned into a pcDNA3.1 vector (pcMYH2.5) (Fig. 4A) . We transfected the pcMYH2.5 plasmid into human rabdomiosarcoma cells. RT-PCR, using a combination of plasmid and MYH14-specific primers (see Methods), showed that the minigene expressed mRNAs both with the inclusion and the exclusion of MYH14 exon 6, with a prevalence of the shorter isoform (Fig. 4B) . The pcMYH2.5 construct was therefore transiently co-transfected with the expression vector for the MBNL1 isoform 41 (pEF1MBNL1 41 ) using a plasmid expressing the EGFP protein (pEGFP) to monitor the transfection efficiency. Total RNA was collected after 48 h and RT-PCR was performed using a combination of MYH14 and plasmid-specific primers to detect RNA processing of MYH14 gene in transfected rabdomiosarcoma cells. The expression of the MBNL1 protein promoted the inclusion of MYH14 exon 6 compared with cells transfected with the minigene alone (Fig. 4B) . The ratios of exon 6 inclusion (MYH14exon6/MYH14total) was 35% ± 2% using the minigene alone and 86% ± 4% when the MBNL1 protein was co-expressed (Fig. 4C) . Taken together, these findings suggest that the MBNL1 protein could specifically promote the inclusion of the MYH14 exon 6 acting on specific cis-elements in the pcMYH2.5 mini-gene genomic sequence.
The NMHC-II protein is down-regulated in DM1 muscle but retains its subcellular localization
In order to study the expression and the localization of the NMHC II-C protein in muscle from DM1 patients and controls, we used an antibody raised to the mouse C-terminal sequence of the protein (kindly provided by Prof. R. Adelstein). The specificity of this antibody among the three NMHCs proteins has been demonstrated by immunoblot and immunoprecipitation analyses (Golomb et al., 2004) . Protein extracts from 8 DM1 skeletal muscle biopsies and 7 controls were tested by Western blot assay using actin for normalization of the samples. Fig. 5A shows immunoblotting incubated with an antibody to NMHC II-C that recognizes a 200 kDa signal expressed in both DM1 and control tissues. Diagram 5B quantifies the integrated optical density of NMHC II-C normalized with actin. Interestingly, in DM1 patients there is a marked reduction of the NMHC II-C level with NMHCII-C/actin median value of 0.24 in DM1 samples and 0.42 in controls. Experiments were repeated three times and the Student's t test demonstrated that the observed difference is statistically significant with a P value b 0.03.
To precisely localize the NMHC II-C protein in the muscle tissues from DM1 patients and controls, we performed immunofluorescence analysis on longitudinal muscle section (n = 3 DM1 samples and n = 3 control samples). For this study, DM1 patients harboring more than 1000 CTG repetitions were chosen. Immunofluorescence showed that the NMHC II-C protein is highly expressed in human skeletal muscle, with no apparent differences between muscle fiber types. In longitudinal sections stained for NMHC II-C, a neat signal with a regular transverse banding pattern, spanning throughout the fiber width, was observed (Fig. 6) . The transverse elements were consistently 0.8-1 μm wide (Fig. 6 ) roughly corresponding to the sarcomeric I band width. Indeed, dual immunolabeling using a combination of antibodies against NMHC II-C and sMHC showed a complete separation of the two fluorescent patterns, with that of NMHC II-C occupying the space between the sMHC, (A bands) (Fig. 6C) . These findings suggest that NMHC II-C has a subcellular location within or in proximity of the I band (Fig. 6 ). This pattern did not differ between DM1 and normal muscles indicating that the aberrant MYH14 splicing does not affect the NMHC II-C muscular distribution, however the intensity of NMHC II-C fluorescent signal seemed lower in DM1 samples than in normal controls according to Western blot analysis (Figs. 6A and B) .
Discussion
The present study reports the expression profile of the MYH14 gene at the mRNA and protein level in DM1 muscle tissue compared to controls. DM1 is a multisystemic disorder that affects the eye, cardiovascular apparatus, endocrine apparatus, gall bladder, testicular system, in addition to the muscle apparatus (Harper et al., 2001 ). Moderate to severe hearing loss has also been identified in some patients with both a peripheral and central level involvement of the Fig. 5 . A) Western blot analysis on muscle lisates from DM1 and controls using an NMHCII-C antibody which recognizes a 200 kDa band. The β-actin protein has been used for the normalization of samples. B) Bar chart reporting the integrated optical density, normalized with β-actin, of the NMHC II-C protein levels in DM1 and in controls muscle samples. The experiment was repeated three times and data are expressed as mean ± standard error of the mean. auditory system (Huygen et al., 1994; Wright et al., 1988) . Recently our group also reported that cochlear impairment in DM1 is present, even in patients without evidence of hearing loss as determined by a standard audiometric analysis (Pisani et al., in press ). Misregulated alternative splicing in DM1 has been demonstrated for several mRNAs which contribute to the muscle, endocrine and cognitive symptoms of patients. The cause of the progressive muscle wasting and other extramuscular manifestations including hearing loss, however, has yet to be completely explained. The high expression of NMHC II-C in skeletal muscle, together with the alternative splicing process of the corresponding mRNA and its involvement in deafness, led us to suggest a possible role of this gene in the molecular pathogenesis of muscle disease and hearing impairment typical of DM1 patients. Our findings show that the aberrant splicing of the MYH14 gene and the down-regulation of the transcript and protein levels in muscle tissues from DM1 patients seem to confirm this hypothesis. The 8 aminoacidlong C1 insert, encoded by MYH14 exon 6, is located into loop 1 of the NMHC protein, in a region critical for binding with actin (Kim et al., 2005) . The predominant expression of the Myh14 Δ6 isoforms observed in DM1 muscles predicts the production of an increasing level of the NMHC II-C0 protein, whose activity and in vitro motility is lower than the inserted isoform, which is predominantly found in controls. Interestingly, the degree of splicing unbalance seems to correlate with the length of CTG repetition and this is in accordance to what has been already observed by our group for other genes (Botta et al., 2008) . Taken together these results strengthen the possibility that the CUG expansion could interfere with the processing of the MYH14 pre-mRNA in a length-dependent manner. We also observed that the Myh14 mouse homologue gene undergoes a splicing alteration in the muscle tissue of transgenic DMSXL mice older than 6 months of age, compared to age-matched healthy littermates. However, the MYH14 splicing patterns observed in DMSXL mice and DM1 patients are opposite. These differences between the two species may arise, among other possibilities, from differences in the muscle-specific distribution of MYH14 mRNA isoforms between mice and humans: non inserted Myh14 isoform predominates in mouse skeletal muscle whereas MYH14 ex6 is the major isoform in the human tissue. We then searched specific sequences for splicing regulation around MYH14 exon 6 and found that there are 3 "YGCU(U/G)Y" motifs and 6 "YGCY" sequences in intron 5 and 6 of the gene. These motifs have been shown to directly interact with the MBNL1 protein and mediate the c-TNT and IR gene alternative splicing (Grammatikakis et al., 2010) . MBNL1 could therefore regulate the alternative splicing of the MYH14 gene leading to the missplicing observed in DM1 muscle. This hypothesis has been confirmed by a minigene assay showing that the overexpression of MBNL1 protein promotes the inclusion of the MYH14 exon 6 acting on specific cis-elements in the MYH14 mini-gene genomic sequence.
In this study, we also observed decreased MYH14 mRNA and protein levels in muscle of DM1 patients. The expression of the NMHC II-C inserted isoform is therefore also lowered by the concomitant reduction of the MYH14 transcript and protein product in DM1 tissues. We suggest that this deleterious effect could be mediated by the CUGcontaining RNA expansions through a transcriptional mechanism driven by direct binding of basic transcription factors (TFs), by epigenetic modifications of the DM1 locus (Ebralidze et al., 2004; López Castel et al., 2011) , or may be due to a reduced stability of the MYH14 transcript in DM1 tissues. Although there is considerable information concerning the role of myosins in cytokinesis (Krendel & Mooseker, 2005; Sellers, 2000) , little is known about the individual role of each of the NMHC isoforms in this process. Studies conducted in Hela and A549 cells show a defect during cytokinesis, cell spreading and adhesion when the motor activity of NMHC proteins is inhibited (Jana et al., 2006) . On the other hand, functional redundancy of the nonmuscle myosin II isoforms in cytokinesis has been reported and all three NMHC II isoforms are capable of rescuing multinucleation and cell dividing defects. The NMHC II-C protein localizes to the intercellular bridge where it is necessary, but not sufficient, for cytokinesis in the dividing process. In mouse and humans, NMHC II-A and NMHC II-B have been described to localize to the Z-lines and intercalated disks in cardiac muscle cells and near to the Z-lines in skeletal muscles (Takeda et al., 2000) . NMHC II-A and II-B seem to have roles in the formation of myofibrils and to both be components of the complex cytoskeletal network required for maintaining the structural integrity of skeletal muscle. Thus far, no immunofluorescence study has been able to determine the muscular localization of the NMHC II-C protein in humans. In the last part of this study we showed that the NMHC II-C protein is strongly expressed in the muscle tissue and more specifically localizes in proximity of the sarcomeric I band, with a pattern of distribution very similar to that showed for NMHC II-A and II-B (Kee et al., 2009) . No significant differences in the localization of the protein have been observed between DM1 and control samples, indicating that the aberrant splicing of the MYH14 gene does not affect the distribution of the NMHC II-C protein. Further studies should clarify the precise subcellular localization and function of NMHC II-C in skeletal muscle fibers and cultures. In particular, it remains to be determined whether NMHC II-C is part of the sarcomeric apparatus or it concurs with other known proteins to form a perimyofibrillar cytoskeletal lattice.
In conclusion, we report for the first time the splicing alteration of the MYH14 gene in DM1 muscle where reduced MYH14 mRNA and protein levels have also been observed. These changes might disrupt the putative function of NMHC II-C in the cytoskeletal machinery and contribute to the pathogenesis of the typical DM1 histopathological features, such as central nuclei, ring fibers, sarcoplasmic masses. In parallel, similar alterations in NMHC II-C in the cochlea of DM1 patients may reduce hair cell contractility, contributing to the hearing impairment phenotype observed in this disease.
